Dr Uwe Schoenbeck, PhD - CSO/SVP, Pfizer - Leading Collaborative Innovation For Unmet Medical Needs

Dr. Uwe Schoenbeck, , () is Chief Scientific Officer, Emerging Science & Innovation (ES&I) and Senior Vice President, Worldwide Research and Development & Medical (WRDM) at Pfizer.

Part of Worldwide Research, Development & Medical, ES&I is charged with enhancing Pfizer’s pipeline through translation of external emerging science into breakthrough therapies for patients and through dedicated outreach to academia, consortia and biotech. Through its Emerging Science Liaisons located around the globe, they work across Pfizer’s Therapeutic Areas to harness external cutting edge pre-clinical assets and breakthrough technologies applying a broad range of partnering vehicles, including research collaborations, consortia, licensing, and acquisitions.

ES&I also engages in equity investments as well as seed investments and formation of new companies. It has a Target Sciences team which is focused on novel target and biology discovery research to introduce differentiated First-in-Class programs with enhanced confidence in rationale into the WRDM portfolio. And through its new Centers for Therapeutic Innovation (CTI - ), ES&I prosecutes cutting edge science sourced from leading academic and medical centers globally, working in close partnership with external PIs and building an exciting pipeline across the range of Pfizer’s core areas.

Dr. Schoenbeck brings fifteen years of pharmaceutical drug development experience to Pfizer’s R&D executive leadership team. Prior to joining the company, he served as Vice President, Emerging R&D Innovation for Wyeth and Vice President, Cardiovascular Research for Boehringer Ingelheim. Before joining industry, he held an Assistant Professor of Medicine position at Brigham & Women’s Hospital, Harvard Medical School. He has served as a reviewer for multiple peer-reviewed journals and has published more than 100 peer-reviewed articles, review articles, book chapters and abstracts with particular contributions in molecular and cell biology, cardiovascular research, immunology and metabolism.

Dr. Schoenbeck earned his from the University of Kiel, Germany, and completed postdoctoral training in the Division of Cardiovascular Medicine, Brigham & Women’s Hospital, Harvard Medical School, before joining as a faculty member.
Be the first to comment